379 results on '"Tan, Daniel Shao Weng"'
Search Results
2. ENABLE-SG (Educate, Nurture, Advise, Before Life Ends for Singapore) as a proactive palliative care model: protocol for a hybrid type 1 effectiveness-implementation randomized wait-list controlled trial
3. REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
4. Retrieval-augmented large language models for clinical trial screening.
5. Molecular tumor board: Real-world experience in a tertiary cancer centre in Singapore.
6. Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers
7. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
8. Bioengineered hydrogels enhance ex vivo preservation of patient-derived tumor explants for drug evaluation
9. Use of Natural Language Processing to Infer Sites of Metastatic Disease From Radiology Reports at Scale
10. Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China
11. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
12. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
13. Obtaining spatially resolved tumor purity maps using deep multiple instance learning in a pan-cancer study
14. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
15. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC)
16. Experimental and bioinformatics considerations in cancer application of single cell genomics
17. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6
18. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
19. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.
20. Retrieval-augmented large language models for clinical trial screening.
21. Addressing cellular heterogeneity in tumor and circulation for refined prognostication
22. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
23. Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer
24. A Decade of Never-smokers Among Lung Cancer Patients—Increasing Trend and Improved Survival
25. Methionine is a metabolic dependency of tumor-initiating cells
26. Assessment of an AI virtual staining model performance across same and serial tissue sections using CD3+T cell ground truth
27. Metronomic chemotherapy: A relook at its basis and rationale
28. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
29. Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.
30. Circulating tumour DNA (ctDNA) burden quantified through low-pass whole genome sequencing as an early pharmacodynamic biomarker of therapeutic response in patients enrolled on phase 1 trials.
31. Identifying correlates of post treatment responses for unresectable locally advanced non-small cell lung cancer (LA NSCLC).
32. Molecular testing in non-small cell lung cancer: A consensus recommendation
33. Inferring cancer disease response from radiology reports using large language models with data augmentation and prompting
34. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
35. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
36. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
37. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer
38. Do elderly patients benefit from enrollment into Phase I Trials?
39. GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers
40. Ultra-High Throughput Enrichment of Viable Circulating Tumor Cells
41. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
42. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
43. Multidisciplinary lung cancer clinic: An emerging model of care
44. Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes
45. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women
46. Publisher Correction: Methionine is a metabolic dependency of tumor-initiating cells
47. PSMA PET Imaging and Therapy in Adenoid Cystic Carcinoma and Other Salivary Gland Cancers: A Systematic Review
48. A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.
49. PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
50. Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.